These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33789592)

  • 41. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
    Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
    J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.
    Hori M; Tanahashi N; Akiyama S; Kiyabu G; Dorey J; Goto R
    J Med Econ; 2020 Mar; 23(3):252-261. PubMed ID: 31687870
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
    BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    Healey JS; Gladstone DJ; Swaminathan B; Eckstein J; Mundl H; Epstein AE; Haeusler KG; Mikulik R; Kasner SE; Toni D; Arauz A; Ntaios G; Hankey GJ; Perera K; Pagola J; Shuaib A; Lutsep H; Yang X; Uchiyama S; Endres M; Coutts SB; Karlinski M; Czlonkowska A; Molina CA; Santo G; Berkowitz SD; Hart RG; Connolly SJ
    JAMA Neurol; 2019 Jul; 76(7):764-773. PubMed ID: 30958508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Embolic strokes of undetermined source: theoretical construct or useful clinical tool?
    Tsivgoulis G; Katsanos AH; Köhrmann M; Caso V; Lemmens R; Tsioufis K; Paraskevas GP; Bornstein NM; Schellinger PD; Alexandrov AV; Krogias C
    Ther Adv Neurol Disord; 2019; 12():1756286419851381. PubMed ID: 31205494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 51. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
    Gibson CM; Hankey GJ; Nafee T; Welsh RC
    Thromb Haemost; 2018 May; 118(S 01):S34-S44. PubMed ID: 29566416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
    Liu CY; Chen HC
    Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
    Mendoza-Sanchez J; Silva F; Rangel L; Jaramillo L; Mendoza L; Garzon J; Quiroga A
    PLoS One; 2018; 13(5):e0196361. PubMed ID: 29723207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.